The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Wendy StockThe ALL Hub spoke to Wendy Stock, The University of Chicago, Chicago, US. We asked, What is the optimal use of asparaginase in adults with acute lymphoblastic leukemia (ALL)?
What is the optimal use of asparaginase in adults with ALL?
Firstly, Stock reviews the data on the outcomes of intensive asparaginase-containing regimens for younger adults with ALL; while they significantly improved outcomes, issues remained around dosing, obesity, and associated toxicities. For the remainder of the discussion, Stock highlights treatment approaches to reduce toxicities in the adult population, including capping the dose of pegylated-asparaginase at 3,750 units and reducing the dose further.
Stock concludes by emphasizing the importance of asparaginase as a key component for young adults with ALL, with ongoing measures being investigated to mitigate toxicities. A study in North America is currently investigating the use of L-carnitine to reduce hepatoxicities.
